The ADAMs: a new therapeutic avenue?
- 1 February 2002
- journal article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 2 (2) , 73-74
- https://doi.org/10.1038/sj.tpj.6500098
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- ADAMs: focus on the protease domainPublished by Elsevier ,2002
- Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall StressCirculation, 2002
- Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapyNature Medicine, 2002
- Seven-transmembrane-spanning receptors and heart functionNature, 2002
- Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytesNature Medicine, 2001
- Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarctionJournal of Clinical Investigation, 2000
- Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failureNature Medicine, 1999
- A metalloprotease-disintegrin, MDC9/meltrin-gamma /ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factorThe EMBO Journal, 1998
- Enhanced expression of heparin-binding EGF-like growth factor and its receptor in hypertrophied left ventricle of spontaneously hypertensive ratsCardiovascular Research, 1998
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990